MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1221 Selected Articles from This Issue

REVIEW

1223 In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL
  Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, and Roddy S. O’Connor

SMALL MOLECULE THERAPEUTICS

1234 Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis
  Anu Gupta, Jarnail Singh, Alfonso García-Valverde, César Serrano, Daniel L. Flynn, and Bryan D. Smith

1246 Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
  Brent A. Willobee, Alexander A. Gaidarski, Austin R. Dosch, Jason A. Castellanos, Xizi Dai, Siddharth Mehra, Fanuel Messaggio, Supriya Srinivasan, Michael N. VanSaun, Nagaraj S. Nagathihalli, and Nipun B. Merchant

1257 Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress

LARGE MOLECULE THERAPEUTICS

1270 PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies

1283 Durvalumab Combined with Immunomodulatory Drugs (IMID) Overcomes Suppression of Antitumor Responses due to IMID-induced PD-L1 Upregulation on Myeloma Cells
  Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, and Hideto Tamura

1295 Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy
  Bin Yi, Hao Cheng, Dorota Wyczechowska, Qingzhao Yu, Li Li, Augusto C. Ochoa, Adam I. Riker, and Yaguang Xi
TARGETING DRUG RESISTANCE

1305 Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas

Hui Zhang, Yongyan Bi, Yuxi Wei, Jiayang Liu, Kudelaidi Kuerban, and Li Ye

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1316 BRAFV600E Mutation in Cell-Free DNA, Rather than in Lesion Tissues, at Diagnosis Is An Independent Prognostic Factor in Children with Langerhans Cell Histiocytosis

Chan-Juan Wang, Lei Cui, Hong-Hao Ma, Dong Wang, Li Zhang, Hong-Yun Lian, Wei-Jing Li, Qing Zhang, Tian-You Wang, Zhi-Gang Li, and Rui Zhang

ABOUT THE COVER

Close-up view of the binding interface between PCA062 (light cyan/violet ribbon), a therapeutic antibody drug conjugate and its target protein antigen, human P-cadherin (gold ribbon), a cell surface glycoprotein highly expressed in several human malignancies. Glutamate E155, a central epitope residue, is unique to human P-cadherin, thus conferring this antibody exquisite selectivity in delivering its toxic payload to P-cadherin expressing cancer cells. Read the full manuscript by Sheng and colleagues on page 1270.
Molecular Cancer Therapeutics

20 (7)

Mol Cancer Ther 2021;20:1221-1323.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/20/7

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/20/7. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.